tarenflurbil has been researched along with 4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kreft, AF; Martone, R; Porte, A | 1 |
| Golshayan, D; Juillerat-Jeanneret, L; Kumar, R | 1 |
2 review(s) available for tarenflurbil and 4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid
| Article | Year |
|---|---|
Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Drug Discovery; Humans; Models, Biological; Protease Inhibitors | 2009 |
Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases.
Topics: Amyloid Precursor Protein Secretases; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinogenesis; Clinical Trials as Topic; Fibrosis; Genes, Tumor Suppressor; Humans; Inflammation; Ligands; Neoplasms; Receptors, Notch; Signal Transduction | 2016 |